Strong execution and potential Cooper Surgical transaction upside offset Asia-Pac weakness, tariffs, and litigation cash outflows.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-06-05 |
| Length | 63 minutes |
| EPS | $1.21 |
| EPS consensus | $1.10 |
| Revenue | $1.1B |
| Revenue consensus | $1.1B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q3 FY25
All COO earnings · Back to COO overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.